* Genetic susceptibility * Atopy: the inherited tendency to develop IgE-mediated immune responses
5
New cards
Allergic Rhinitis (Hay Fever) Pathophysiology
* Step 1: Sensitization * Allergen-specific IgE produced by B-lymphocytes * Step 2: Early phase reaction * Occurs within minutes * Upon re-exposure to allergen * Mast cell degranulation and mediator release * Step 3: Late phase reaction * Occurs hours to days after exposure * Influx of inflammatory cells
* Guidelines recommend nasal corticosteroid over montelukast for allergic rhinitis * As monotherapy * comparable to or inferior to oral antihistamines * inferior to nasal corticosteroids * In combination with antihistamine inferior to nasal corticosteroid
* Administration of specific allergens extract * Relieves symptoms 3+ years after discontinue injections * Effective in allergic rhinitis caused by tree pollens, grass pollens, weed pollens, mold spores, dust mites, and animal dander
95
New cards
Immunotherapy (“Allergy Shots”) Are Considered When
* Allergen exposure is unavoidable * Allergic response all year or most of the year * Difficulty treating pharmacologically * Significant potential benefit (children and young adults)
96
New cards
Immunotherapy (“Allergy Shots”) Guidelines
Guidelines recommend referring for potential immunotherapy if inadequate response to pharmacologic therapy
97
New cards
Immunotherapy (“Allergy Shots”) Process
1-2 injections weekly (dose-building), then tapered to once monthly
98
New cards
Immunotherapy (“Allergy Shots”) Cautions
* Major risk: anaphylaxis * Beta-blocker therapy – reduce epinephrine response * Chronic medical conditions that reduce ability to survive a reaction